FY2027 EPS Estimates for Novartis Cut by Erste Group Bank

Novartis AG (NYSE:NVS) – Equities researchers at Erste Group Bank decreased their FY2027 earnings per share (EPS) estimates for shares of Novartis in a report released on Wednesday, July 15th. Erste Group Bank analyst H. Engel now expects that the company will earn $9.67 per share for the year, down from their prior estimate of $9.76. The consensus estimate for Novartis’ current full-year earnings is $8.75 per share.

Novartis (NYSE:NVS) last announced its earnings results on Monday, April 27th. The company reported $1.99 EPS for the quarter, missing the consensus estimate of $2.11 by ($0.12). Novartis had a return on equity of 38.82% and a net margin of 24.87%.The company had revenue of $13.52 billion for the quarter, compared to analyst estimates of $13.44 billion. During the same quarter last year, the business posted $2.28 earnings per share. The business’s quarterly revenue was down .9% on a year-over-year basis.

A number of other equities research analysts have also commented on the stock. Morgan Stanley raised their price objective on shares of Novartis from $143.00 to $170.00 and gave the stock an “overweight” rating in a report on Thursday, March 26th. Weiss Ratings cut Novartis from a “buy (a-)” rating to a “buy (b)” rating in a report on Wednesday, April 29th. Seven investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $141.20.

Novartis Stock Up 0.7%

Novartis stock opened at $153.78 on Friday. The company has a 50 day moving average of $151.41 and a 200-day moving average of $151.61. The company has a quick ratio of 0.65, a current ratio of 0.85 and a debt-to-equity ratio of 0.96. Novartis has a twelve month low of $112.34 and a twelve month high of $170.46. The stock has a market capitalization of $293.44 billion, a PE ratio of 22.03, a price-to-earnings-growth ratio of 2.65 and a beta of 0.45.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of NVS. J.W. Cole Advisors Inc. lifted its holdings in shares of Novartis by 0.6% during the fourth quarter. J.W. Cole Advisors Inc. now owns 10,577 shares of the company’s stock valued at $1,348,000 after purchasing an additional 64 shares in the last quarter. Roundview Capital LLC increased its holdings in Novartis by 2.5% in the 4th quarter. Roundview Capital LLC now owns 2,711 shares of the company’s stock worth $374,000 after buying an additional 66 shares in the last quarter. IMA Advisory Services Inc. increased its holdings in Novartis by 10.9% in the 4th quarter. IMA Advisory Services Inc. now owns 710 shares of the company’s stock worth $98,000 after buying an additional 70 shares in the last quarter. Moody National Bank Trust Division raised its position in Novartis by 4.2% in the 2nd quarter. Moody National Bank Trust Division now owns 1,802 shares of the company’s stock worth $282,000 after buying an additional 72 shares during the last quarter. Finally, Abundance Wealth Counselors lifted its stake in Novartis by 0.4% during the 4th quarter. Abundance Wealth Counselors now owns 16,927 shares of the company’s stock valued at $2,334,000 after acquiring an additional 73 shares during the period. 13.12% of the stock is owned by institutional investors and hedge funds.

Novartis Company Profile

Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide.

The company’s activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies.